Pharmaceutic reagents that specifically target mammalian target of rapamycin (mTOR) have been approved by the Food and Drug Administration (FDA) of the United States for treating advanced renal cancer, progressive or metastatic pancreatic cancer, and breast cancer in post-menopausal women with estrogen receptor (ER)- or progesterone receptor (PR)-positive and human epidermal growth factor receptor 2 (HER2)-negative lesions. mTOR is aberrantly activated through either the activation of phosphatidylinositide 3-kinases (PI3K)/AKT signaling or the inactivation of LKB1/AMPK/TSC signaling. Here, we focus on the activation of mTOR through the inactivation of LKB1 signaling.

LKB1 as a Serine/Threonine Kinase {#s2}
=================================

The liver kinase B1 (*LKB1*) gene is located on chromosome 19p13.3 and spans 23 kb. It contains 10 exons, 9 of which are protein-coding, and the gene is transcribed in the telomere-to-centromere direction[@b1]. The *LKB1* transcript is 3.1 kb in length. It is ubiquitously expressed in all fetal and adult tissues, with high expression levels in the pancreas, liver, and skeletal muscle[@b2]. It encodes a 436-amino acid protein that comprises two nuclear localization sequences, a kinase domain (residues 50--319), and a putative carboxy-terminal regulatory domain. It is evolutionarily conserved with closely related orthologues in mouse, *Xenopus*[@b3], *Drosophila*, and *C. elegans* (Par4)[@b4].

LKB1 is a serine/threonine kinase and has at least 13 potential substrates in the AMP-activated protein kinase (AMPK) subfamily, such as AMPK, brain-specific kinase (BRSK), and salt-inducible kinase (SIK)[@b5]. Although LKB1 is present in both the nucleus and cytoplasm of cells, LKB1 can exert its kinase activities in only the cytoplasm. This is because the phosphorylation of AMPK by LKB1 requires its interactions with two adaptor proteins, Ste20-related adaptor (STRAD) and mouse protein 25 (MO25). STRAD, which has both α and β isoforms, is a pseudokinase that lacks key residues required for catalyzing protein phosphorylation. STRAD is found only in the cytosol, and its binding to LKB1 activates the autophosphorylating kinase activity of LKB1 and targets LKB1 to the cytosol[@b6]. MO25 (α or β) binds to STRAD and stabilizes the STRAD-LKB1 complex [@b7]. The LKB1-STRADα-MO25α complex, but not LKB1 alone, can phosphorylate the AMPKα subunit at Thr172[@b8].

LKB1 kinase activity is also regulated by phosphorylation. Thr189 is usually autophosphorylated, but this modification can be abrogated by introducing a mutation at this site[@b9]. LKB1 can also be phosphorylated at Ser31, Ser325, Thr336, Thr366, and Ser428 (Ser431 in mice)[@b2],[@b10], and mutations at Thr336 and Ser428 impair the ability of LKB1 to suppress cell growth in LKB1 overexpression studies[@b2],[@b10],[@b11]. The aberrant activation of BRAF by V600E mutation and its downstream target ribosomal S6 kinase 2 (RSK2) inactivates LKB1 protein function in melanoma cells through the phosphorylation of LKB1 at Ser324 and Ser428[@b12],[@b13].

LKB1 as a Regulator of mTOR {#s3}
===========================

Tremendous progress over the last few years has linked LKB1 to the regulation of mTOR. mTOR is an evolutionarily conserved serine/threonine kinase that plays a central role in the regulation of cell growth and proliferation, which is achieved in part through the regulation of protein translation. Two key downstream targets of mTOR are p70 ribosomal S6 kinase (S6K) and eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1). mTOR promotes translational initiation by phosphorylating S6K, which stimulates the translation of ribosomal proteins, and by phosphorylating 4E-BP1. The phosphorylation of 4E-BP1 releases eIF4E, which is then free to form a complex with eIF4F, promoting cap-dependent translation.

LKB1 is linked to mTORC1 through the sequential activation of AMPK and the tumor suppressor tuberin (TSC2)[@b14]--[@b16] ([**Figure 1**](#cjc-32-08-427-g001){ref-type="fig"}). AMPK is a metabolic master regulator that is activated in response to reduced energy availability \[high cellular adenosine monophosphate (AMP): adenosine triphosphate (ATP) ratios\] or hypoxic stress[@b17],[@b18]. AMPK exists as a heterotrimer composed of a catalytic domain (α) and two regulatory domains (β and γ). Phosphorylation of the AMPKα subunit in the activation loop at Thr172 by LKB1 is essential for the catalytic activity of AMPK[@b8],[@b14]--[@b16],[@b19]. LKB1 acts upstream of AMPK, as indicated by genetic evidence showing that AMPK activation in response to treatment with 5-aminoimidazole-4-carboxamide riboside (AICAR), an AMP analog that increases the perceived AMP:ATP ratio, is compromised in *Lkb1*^−/−^ mouse embryonic fibroblasts (MEFs) and can be restored following reconstitution of LKB1[@b8].

![The regulation of mammalian target of rapamycin (mTOR) by the LKB1/AMPK signaling pathway.\
Environmental stress leads to the activation of AMP-activated protein kinase (AMPK) by liver kinase B1 (LKB1), which subsequently activates hamartin (TSC1)/tuberin (TSC2) complex. The activation of this pathway down-regulates mTOR activity, which leads to cell growth arrest. mTOR activity can also be regulated by growth factors through the PI3K/PTEN/AKT pathway.](cjc-32-08-427-g001){#cjc-32-08-427-g001}

*TSC1* and *TSC2* (also known as hamartin and tuberin, respectively) are tumor suppressor genes involved in tubular sclerosis, a familial cancer syndrome that is associated with benign renal polyps and exhibits some clinical similarities to Peutz-Jeghers syndrome (PJS). TSC2 is a GTPase-activating protein (GAP) for the ras-like GTPase Rheb. GTP-bound Rheb stimulates mTOR activity through an unknown mechanism. The phosphorylation of TSC2 at Thr1227 and Ser1345 by AMPK activates TSC2 GAP activity, shifting the balance toward Rheb-GDP and thus suppressing mTOR activity[@b20]--[@b22].

mTOR and the phosphorylation of S6K and 4E-BP1 are rapidly induced by mitogens, insulin, and nutrients. In this context, the activation of mTOR is mediated by the PI3K/AKT pathway. AKT stimulates mTOR through the phosphorylation and inactivation of TSC2. AKT can also phosphorylate mTOR directly (at S2448). Thus, the tumor suppressor complex TSC1/TSC2, together with mTOR, constitutes a key integration point for mitogenic and stress-activated signals. The activation of the LKB1/AMPK/TSC pathway under conditions of low energy or insufficient nutrient availability thus overrides the mitogenic signals transmitted by the PI3K/AKT pathway. In this sense, the LKB1/AMPK/TSC pathway can be thought of as a cellular stress-activated "checkpoint" that prevents energy- or nutrient-consuming processes, such as protein translation or cell division, from occurring under suboptimal conditions. Indeed, *Lkb1*^−/−^ or *Tsc2*^−/−^ MEFs undergo apoptosis in response to low glucose, whereas their wild-type counterparts are protected from this event[@b20],[@b23].

Loss of LKB1 Kinase Activity Leads to Aberrant mTOR Activation in a Variety of Tissues {#s4}
======================================================================================

*LKB1* was originally identified as the causal gene mutation in the inherited cancer syndrome PJS, an autosomal-dominant disease that is characterized by benign hamartomatous polyposis of the gastrointestinal (GI) tract, hyperpigmentation of mucosal membranes, and an increased risk of intestinal malignancies[@b1],[@b24]. PJS patients are also at an increased risk of developing other cancers, including cancers of the lung, breast, pancreas, uterus, ovary, cervix, and testis[@b25]--[@b28]. It is estimated that PJS patients have a 93% lifetime risk of cancer, with a mean age of cancer diagnosis at 43 years old. Most PJS-associated *LKB1* mutations are in the highly conserved kinase domain. Almost all PJS point mutants that have been tested for *in vitro* kinase activity have been inactive, consistent with the hypothesis that PJS-associated mutations disrupt LKB1 enzymatic function. The intestinal polyps in PJS patients were shown to have up-regulated mTORC1 signaling[@b29], supporting that the genetic inactivation of *LKB1* promotes aberrant activation of mTORC1 signaling in GI polyps. Interestingly, the loss of *LKB1* in stromal cells may also contribute to the formation of GI polyps; the loss of murine *Lkb1* in mesenchymal cells also leads to GI polyps that are indistinguishable from those in a PJS mouse model[@b30].

The negative regulation of mTORC1 signaling by LKB1 is not limited to GI polyps. The conditional knockout of *Lkb1* in the beta cell compartment of pancreatic islets leads to elevated mTOR activity, increased beta cell mass, and enhanced glucose tolerance[@b31]. Interestingly, LKB1 controls beta cell size via the mTOR pathway but regulates cell polarity through an mTOR-independent mechanism[@b32]. Cardiac myocyte-specific *Lkb1* knockout leads to decreased AMPK phosphorylation and increased mTOR activity in both the atria and ventricles of *Lkb1*-deficient mice. These mice display cardiac dysfunction and atrial fibrillation and usually die within 6 months[@b33]. A somatic testicular cell-specific deletion of *Lkb1* leads to germ cell loss, accompanied by defects in Sertoli cell polarity and the testicular junctional complex. Additionally, AMPK is inhibited and mTOR signaling is activated in *Lkb1*-null testes[@b34].

Because LKB1 kinase activity requires the adaptor protein STRAD, it might be expected that hereditary *STRAD* mutations have an effect similar to that of *LKB1* mutation. Indeed, homozygous deletion of *STRADα* leads to a rare human autosomal-recessive disorder called polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE) syndrome, which is characterized by abnormal brain development, cognitive disability, and intractable epilepsy[@b35]. Neurons in the cortex of patients with PMSE exhibit abnormal nuclear localization of LKB1, and these patients have high levels of ribosomal S6 phosphorylation in large cells within the frontal cortex, basal ganglia, hippocampus, and spinal cord, consistent with the aberrant activation of mTORC1 signaling in the brain[@b36].

Loss of LKB1 as a Mechanism for mTOR Dysregulation in Human Cancers {#s5}
===================================================================

Considering the pivotal role of mTOR as an integrator of cell growth and cell stress signals, it stands to reason that acquired mutations that lead to the activation of mTOR survival signaling would provide a selective advantage during tumor progression. Indeed, most major forms of cancer exhibit acquired alterations in the genes that either promote mTOR activation directly or inactivate pathways that negatively regulate mTOR. As noted above, mTOR is positively regulated by mitogenic stimuli through the PI3K/AKT pathway. Growth factors, such as insulin, act through receptor tyrosine kinases to activate PI3K, which catalyzes the conversion of phosphatidylinositol(4,5)-bisphosphate (PIP2) to phosphatidylinositol(3,4,5)-trisphosphate (PIP3). PIP3 stimulates AKT kinase activity, which in turn stimulates mTOR by phosphorylating and inactivating TSC2. The tumor suppressor phosphatase and tensin homolog (PTEN) acts as a negative regulator of this process through its function as a lipid phosphatase that converts PIP3 back to PIP2. Constitutive activation of the PI3K/AKT pathway is common in human cancers and can occur due to activating mutations in *PIK3CA* (the p110α catalytic subunit of PI3K) or through the inactivation of PTEN by mutation or promoter methylation. In fact, the somatic mutation rates of *PIK3CA* plus *PTEN* vary strikingly among cancers; whereas the rate exceeds 30% in many common tumor types (brain, colon, and breast tumors), it is \<15% in non-small cell lung cancer (NSCLC)[@b37]. Although *PTEN* mutations have been observed in approximately 15% of NSCLC cell lines, they are rarely observed in primary tumors[@b38]. Likewise, phosphorylated (activated) AKT was observed in less than 20% of NSCLCs[@b39],[@b40]. In contrast, although allelic loss at the *LKB1* locus (chromosome 19p13.3) is observed in many cancers, somatic mutations in *LKB1* are relatively rare in most common tumor types, including colon[@b41], breast[@b42], ovarian[@b43], and brain[@b44] cancers. However, mutations in *LKB1* do occur in a small fraction of malignant melanomas[@b45],[@b46], cervical cancers[@b47],[@b48], and pancreatic cancers[@b49],[@b50]. The exception is in NSCLCs, among which somatic mutations in *LKB1* have been initially observed in 30% of adenocarcinomas[@b51],[@b52], 15% of large cell carcinomas[@b53], and 19% of squamous carcinomas[@b54]. A recent paper suggested that the complete inactivation of the *LKB1* gene by either homozygous deletion or loss of heterozygosity due to somatic mutation occurs in 39% of NSCLCs[@b55]. High-throughput next-generation sequencing analyses have also indicated that *LKB1* is frequently inactivated in adenocarcinoma and squamous carcinoma of the lung[@b56]--[@b58]. The loss of *LKB1* in lung cancer cell lines associates with the losses of the STRADα protein and energetic stress-induced AMPK activation, and the aberrant activation of mTOR signaling[@b59]--[@b61]. Hence, the bi-allelic inactivation of LKB1 appears to be a major mechanism for the dysregulation of mTOR in NSCLC.

Rapamycin as a Treatment Option in *Lkb1*-null Tumor Mouse Models {#s6}
=================================================================

Because the loss of LKB1 promotes the activation of mTORC1 signaling, rapamycin has been evaluated as a therapeutic option in several conditional *Lkb1*-knockout mouse models ([**Table 1**](#cjc-32-08-427-t01){ref-type="table"}). In an *Lkb1*^+/−^ PJS mouse model, rapamycin was shown to efficiently decrease the tumor burden of existing large polyps[@b62] and reduce the onset of polyposis[@b63]. Endometrium-specific deletion of *Lkb1* gene by Sprr2f-Cre revealed that bi-allelic inactivation of LKB1 is required for the formation of highly invasive endometrial adenocarcinomas. These tumors exhibit elevated mTOR signaling, and rapamycin treatment not only slowed disease progression but also led to the regression of pre-existing tumors[@b64]. In mouse urothelium, conditional deletions of *Lkb1* or *Pten* alone failed to reveal any morphologic or growth differences, but the combination of *Lkb1* and *Pten* deletion significantly elevated mTOR activity, EMT transition, and bladder tumor formation. Rapamycin treatment significantly reduced mitosis and tumor formation through the down-regulation of mTOR activity[@b65].

###### The effect of rapamycin treatment in various *Lkb1*-deficient mouse models

  Mouse model                                                   Effect of rapamycin treatment                    Reference
  ------------------------------------------- ----------------------------------------------------------------- -----------
  *Lkb1*^+/−^ PJS                                                Tumor burden is decreased.                       [@b62]
                                                                 Polyposis onset is reduced.                      [@b63]
  *Lkb1*^−/−^ endometrial cancer               Disease progression is slowed; pre-existing tumor is regressed.    [@b64]
  *Lkb1*^−/−^ *Pten*^−/−^ urothelium cancer                      Tumor formation is reduced.                      [@b65]
  *Lkb1*^−/−^ prostate cancer                      mTOR is down-regulated by a LKB1-independent mechanism.        [@b66]
  *Kras* (G12D) *Lkb1*^−/−^ lung cancer                             mTOR is up-regulated.                         [@b54]
                                               Cancer metastasis occurs through an mTOR independent mechanism.    [@b67]

It is important to note that several *Lkb1*-null induced tumors are not driven by elevated mTOR activity. For example, the conditional knockout of *Lkb1* in murine prostate lobes leads to 100% atypical hyperplasia and 83% prostate intraepithelial neoplasia (PIN) at the anterior prostate within 4 months[@b66]. However, these PIN lesions feature increased cytoplasmic phosphorylated AMPK and a loss of nuclear phosphorylated mTOR, suggesting that an alternative mechanism accounts for the activation of AMPK and suppression of mTOR and that aberrant activation of mTOR signaling is not related to the formation of these lesions.

*LKB1* mutations are frequently observed in NSCLC, but *Lkb1* inactivation alone in mice was insufficient to induce pulmonary neoplasia[@b54]. Currently, the most relevant mouse lung cancer model is the inactivation of *Lkb1* in a mutant *Kras* background, which leads to the formation of adeno-, squamous, and large-cell carcinomas of the lung and promotes tumor metastasis[@b54]. In these *Lkb1*-null tumors, the Nedd9 protein level is elevated and is essential for tumor metastasis[@b67]. *LKB1* negatively regulates *Nedd9* gene expression through its substrate SIK2 but not the AMPK-mTOR axis. Consistent with this mechanism, rapamycin treatment fails to alter NEDD9 protein levels in this mouse model[@b54].

Conclusions {#s7}
===========

In summary, LKB1 negatively regulates mTOR signaling through its substrate AMPK, and the loss of LKB1 leads to the aberrant activation of mTOR in a variety of tissues. LKB1 loss-associated mTOR activation is the driving force in several mouse models of tumorigenesis, such as the formation of PJS polyps, endometrial adenocarcinomas, and bladder cancers, and rapamycin treatment appears to be effective in these disease models. However, LKB1 has other downstream targets, and the inactivation of LKB1 can promote tumorigenesis in an mTOR-independent manner in other tumor types. In these tumors, the targeted inhibition of mTOR is unlikely to be a viable therapeutic option.
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